Advertisement

Fluorouracil and Leucovorin in Advanced Breast Cancer

  • James H. Doroshow
  • Kim Margolin
  • Lucille Leong
  • Steven Akman
  • Robert MorganJr.
  • James Raschko
  • George Somlo
  • Victor Hamasaki
  • Eleanor Womack
  • Edward Newman
  • C. Ahn
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 339)

Abstract

It is clear from the studies summarized above that the combination of leucovorin and 5-FU can salvage 15–20% of heavily-pretreated patients with advanced breast cancer. In previously-untreated patients, the combination generates objective responses in over one third of women with a very modest and acceptable toxicity profile. It is also clear that the addition of mitoxantrone or cisplatin to 5-FU and leucovorin produces very effective regimens, that, at least in the case of the platinum combination, may be quite active in patients who have failed therapy with an anthracycline. All of these recently-completed trials, suggest that studies currently in progress aimed at improving the biochemical modulation of the fluoropyrimidines have real promise for enhancing the therapy of patients with advanced breast cancer further.

Keywords

Breast Cancer Clin Oncol Advanced Breast Cancer Objective Response Rate Biochemical Modulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Henderson IC, Hayes DF, Come S, et al: New agents and new medical treatments for advanced breast cancer. Semin Oncol 14: 34–64, 1987PubMedGoogle Scholar
  2. 2.
    Ansfield FJ, Ramirez G, Mackman S, et al: A ten-year study of 5-fluorouracil in disseminated breast cancer with clinical results and survival times. Cancer Res 29: 1062–1066, 1969PubMedGoogle Scholar
  3. 3.
    Huan S, Padzur R, Singhakowinta A, et al: Low-dose continuous infusion 5-fluorouracil: evaluation in advanced breast carcinoma. Cancer 63: 419–422, 1989PubMedCrossRefGoogle Scholar
  4. 4.
    Marini G, Simoncini E, Zaniboni A, et al: 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update. Oncology 44: 336–340, 1987PubMedCrossRefGoogle Scholar
  5. 5.
    Doroshow JH, Leong L, Margolin K, et al: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439–444, 1989PubMedGoogle Scholar
  6. 6.
    Swain SM, Lippman ME, Egan EF, et al: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890–899, 1989PubMedGoogle Scholar
  7. 7.
    Loprinzi CL, Ingle JN, Schaid DJ, et al: 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. Am J Clin Oncol 14: 30–32, 1991PubMedCrossRefGoogle Scholar
  8. 8.
    Margolin K, Doroshow J, Green S, et al: Treatment of advanced breast cancer with 5-FU and high-dose folinic acid. Proc Amer Soc Clin Oncol 10: 59, 1991 (abstr)Google Scholar
  9. 9.
    Margolin KA, Doroshow JH, Akman SA, et al: Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J Clin Oncol 10: 1278–1283, 1992PubMedGoogle Scholar
  10. 10.
    Fine S, Erlichman C, Kaizer L, et al: Phase II trial of 5FU + folinic acid (FA) as first line treatment for metastatic breast cancer. Proc Amer Soc Clin Oncol 7: 41, 1988 (abstr)Google Scholar
  11. 11.
    Cowan JD, Neidhart J, McClure S, et al: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83: 1077–1084, 1991PubMedCrossRefGoogle Scholar
  12. 12.
    Ellis GK, Green S, Schulman S, et al: Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study. Cancer 68: 934–939, 1991PubMedCrossRefGoogle Scholar
  13. 13.
    Palmeri S, Gebbia V, Russo A, et al: Cyclophosphamide plus epidoxorubicin and 5-fluorouracil with folinic acid as a novel treatment in metastatic breast cancer: preliminary results of a phase II study. J Chemother 3: 176–179, 1991PubMedGoogle Scholar
  14. 14.
    Hainsworth JD, Andrews MB, Johnson DH, et al: Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 9: 1731–1735, 1991PubMedGoogle Scholar
  15. 15.
    Jones SE, Mennel RG, Brooks B, et al: Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 9: 1736–1739, 1991PubMedGoogle Scholar
  16. 16.
    Ardalan B, Sridhar KS, Benedetto P, et al: A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer 68: 1242–1246, 1991PubMedCrossRefGoogle Scholar
  17. 17.
    Bhalla K, Birkhofer M, Bhalla M, et al: A phase I study of a combination of allopurinol, 5-fluorouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal and breast cancer. Am J Clin Oncol 14: 509–513, 1991PubMedCrossRefGoogle Scholar
  18. 18.
    Pronzato P, Amoroso D, Ardizzoni A, et al: Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer. Am J Clin Oncol 10: 404–406, 1987PubMedCrossRefGoogle Scholar
  19. 19.
    Leong L, Doroshow J, Akman S, et al: Phase II trial of 5-fluorouracil (5-FU), folinic acid (FA), and cis-platinum (CDDP) in metastatic breast cancer. Proc Amer Soc Clin Oncol 10: 65, 1991 (abstr)Google Scholar
  20. 20.
    Sledge GW, Jr., Loehrer PJ, Sr., Roth BJ, et al: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6: 1811–1814, 1988PubMedGoogle Scholar
  21. 21.
    Allegra CJ, Mayer A, Reed E, et al: Therapy of patients with metastatic breast cancer (MBC) with 5-fluorouracil (FU), leucovorin (L), and carboplatin (CBDCA). Proc Amer Soc Clin Oncol 8: 54, 1989 (abstr)Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • James H. Doroshow
    • 1
  • Kim Margolin
    • 1
  • Lucille Leong
    • 1
  • Steven Akman
    • 1
  • Robert MorganJr.
    • 1
  • James Raschko
    • 1
  • George Somlo
    • 1
  • Victor Hamasaki
    • 1
  • Eleanor Womack
    • 1
  • Edward Newman
    • 1
  • C. Ahn
    • 1
  1. 1.Departments of Medical Oncology, Pediatrics, and BiostatisticsCity of Hope Cancer Research CenterDuarteUSA

Personalised recommendations